基本信息
浏览量:0
职业迁徙
个人简介
Grants
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed With Epilepsy awarded by Xenon Pharmaceuticals Inc. 2023 - 2028
The overlap of speech production and verbal working memory awarded by National Institutes of Health 2023 - 2028
Promoting Effective Self-Management of Chronic Pain with mHealth Neurofeedback awarded by National Institutes of Health 2022 - 2027
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures awarded by Xenon Pharmaceuticals Inc. 2023 - 2025
MARN - Protocol 1042-SE-3004_Imaging awarded by Marinus Pharmaceuticals, Inc. 2023 - 2025
Epilepsy in Uganda: Clinical characterization and co-morbidities, their relation to stigma among adolescents and impact of a community-based intervention awarded by Makerere University 2021 - 2024
Epilepticus_EEG Coordinating Ctr. awarded by Marinus Pharmaceuticals, Inc. 2020 - 2023
Phase I Single Ascending Dose and Multiple Ascending Dose Study of 2R,6R-Hydroxynorketamine awarded by National Institutes of Health 2018 - 2023
Neuromodulatory Treatments for Pain Management in Complex TBI using Mobile Technology awarded by Department of Defense 2017 - 2022
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy awarded by Biogen, Inc. 2018 - 2021
A Multicenter, Open-label, Long-term, Safety, Tolerability, and Efficacy Study of XEN1101 in Adults Diagnosed With Epilepsy awarded by Xenon Pharmaceuticals Inc. 2023 - 2028
The overlap of speech production and verbal working memory awarded by National Institutes of Health 2023 - 2028
Promoting Effective Self-Management of Chronic Pain with mHealth Neurofeedback awarded by National Institutes of Health 2022 - 2027
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures awarded by Xenon Pharmaceuticals Inc. 2023 - 2025
MARN - Protocol 1042-SE-3004_Imaging awarded by Marinus Pharmaceuticals, Inc. 2023 - 2025
Epilepsy in Uganda: Clinical characterization and co-morbidities, their relation to stigma among adolescents and impact of a community-based intervention awarded by Makerere University 2021 - 2024
Epilepticus_EEG Coordinating Ctr. awarded by Marinus Pharmaceuticals, Inc. 2020 - 2023
Phase I Single Ascending Dose and Multiple Ascending Dose Study of 2R,6R-Hydroxynorketamine awarded by National Institutes of Health 2018 - 2023
Neuromodulatory Treatments for Pain Management in Complex TBI using Mobile Technology awarded by Department of Defense 2017 - 2022
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy awarded by Biogen, Inc. 2018 - 2021
研究兴趣
论文共 79 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Clinical Neurophysiology (2024): 2-8
引用0浏览0WOS引用
0
0
Nature and science of sleep (2023): 593-606
引用1浏览0WOS引用
1
0
Jaime R López, Linda Kelly, Judy Ahn-Ewing,Ron Emerson, Carrie Ford,Clare Gale, Jeffery H Gertsch,Aatif Husain,John Kincaid,Meledy Kise, Adam Kornegay, Joseph J Moreira,
Handbook of Clinical Neurophysiology (2022): 271-292
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn